THERAPY DOSSIER · th-f24af45370b6

1NMPP1

Drug · No confident ChEMBL match; cell-permeable ATP-analogue inhibitor of engineered analog-sensitive kinases (research tool)

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: No confident ChEMBL match; cell-permeable ATP-analogue inhibitor of engineered analog-sensitive kinases (research tool)
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: 1NM-PP1
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23155176 ↗2012Mixed findings

Critical role of trkB receptors in reactive axonal sprouting and hyperexcitability after axonal injury.

MouseTBIPenetrating / ballistictrkB(F616A) knock-in miceSystemic administrationAdministered for 7 days after the lesion

Model: Penetrative traumatic brain injury modelled by transection of the Schaffer collateral pathway

1NMPP1 given for 7 days after the lesion reduced trkB activation, GAP43 upregulation and injury-induced hyperexcitability, but also prevented the recovery of CA3 to CA1 synaptic transmission seen in untreated lesioned mice.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…